Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung. 1983

Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi

Serum neuron-specific enolase (NSE) was measured in 80 normal subjects, 20 patients with small cell carcinoma of the lung (SCCL) and 54 patients with non-small cell carcinoma (non-SCCL). The mean value in the control group was 2.1 +/- 0.4 ng/ml (range, from 1.3 to 3.0 ng/ml). Serum levels exceeding 7.5 ng/ml were tentatively defined as positive. Thirteen of 20 patients (65%) with SCCL had positive serum NSE levels, whereas 6 of 54 patients (11%) with non-SCCL had positive levels. Positive NSE in sera of patients was observed only in patients with advanced clinical stage of SCCL or non-SCCL. No correlation between serum NSE levels and metastatic sites could be found. The serum NSE levels in subtypes of SCCL were positive in 9 of 10 patients with oat cell carcinoma and 4 of 10 patients with intermediate cell carcinoma. Histological types of all positive cases with non-SCCL included large cell carcinoma. Serum NSE levels changed in parallel with the clinical course during the treatments. The data suggested that serum NSE may be a useful marker for monitoring the clinical course of lung carcinoma, especially of SCCL. Furthermore, the detection of NSE in non-SCCL is of interest in relation to the histogenesis of lung carcinomas which exhibit the properties of neuroendocrine tumors.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D018288 Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) Carcinoma, Oat Cell,Oat Cell Carcinoma,Small Cell Carcinoma,Carcinomas, Oat Cell,Carcinomas, Small Cell,Oat Cell Carcinomas,Small Cell Carcinomas

Related Publications

Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
May 1984, Gan no rinsho. Japan journal of cancer clinics,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
February 1988, Nihon Kyobu Shikkan Gakkai zasshi,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
August 1993, Biochemical Society transactions,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
January 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
December 1994, Harefuah,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
January 1993, European urology,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
March 1990, Cancer,
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
October 1993, Lancet (London, England),
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
November 1988, Deutsche medizinische Wochenschrift (1946),
Y Ariyoshi, and K Kato, and Y Ishiguro, and K Ota, and T Sato, and T Suchi
January 1984, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!